TaiRx Business Summary

TaiRx (6580.TWO) is a Taiwan-based biopharmaceutical company that operates a dual-axis revenue model combining clinical-stage drug development with commercialized healthcare products. The company generates immediate revenue through the sale of Zelnite (a selenium injection for deficiency) and its consumer health brand, Hao Xi Jia, which markets the Selite supplement line. Its primary business segments are focused on oncology and critical care, led by its flagship candidate CVM-1118 (Foslinanib), a small-molecule inhibitor targeting vasculogenic mimicry in neuroendocrine tumors and hepatocellular carcinoma. TaiRx also maintains a robust pipeline including Rexis for sepsis adjuvant therapy and a proprietary Antibody-Drug Conjugate (ADC) platform. Within the Taiwanese biotech landscape, TaiRx competes directly with oncology-focused firms such as OBI Pharma, Medigen Biotechnology, and PharmaEssentia, positioning itself as a specialized developer of first-in-class therapies for unmet needs in aggressive cancer progression and systemic inflammation. The company was co-founded by President and CEO Dr. Du-Shieng Chien and Senior VP Dr. Yi-Wen Chu, both of whom bring extensive pedigree from global pharmaceutical and research institutions. Dr. Chien previously held senior R&D leadership roles at Bayer, Allergan, and Neurogen, while Dr. Chu is a recognized expert in cancer biology from the National Health Research Institutes. The leadership team is further strengthened by Chairman Andrew Lin, the former Chairman of Lotus Pharmaceutical and a veteran of JPMorgan and McKinsey, and CFO Jackson Huang, who oversees the firm’s capital strategy. TaiRx is backed by a notable group of institutional investors and strategic partners, including Formosa Laboratories, O-Bank, China Development Financial, and Top Taiwan Venture Capital, reflecting strong domestic support for its transition from a pure R&D entity to a commercially active biopharma player.